الفهرس | Only 14 pages are availabe for public view |
Abstract CHAPTER: VI English Summary Cancer is a class of disease characterized by uncontrolled cell division and the ability of these cells to invade other tissue, either by direct growth into adjacent tissue (invasion) or by migration of cells to distant sites (metastasis). This unregulated growth is caused by a series of acquired or inherited mutations of DNA within cells, damaging genetic information that define the cell function and removing normal control of cell division, it is well known that cancer is a very dangerous disease which eventually leads to the death. Scientists direct their effort to cancer therapy. Chemotherapy, radiotherapy hormonal therapy are representatives of cancer treatment but all these have many side effect on the human body and can not discriminate between the normal and cancer cells. Recently the scientists all over the world directed their effort to use natural products as therapeutic drugs for many diseases which cancer is one of them; because of their effectiveness towards cancer treatment with low side effects and powerful ability to distinguish between normal and cancer cells. Lectin is a natural product found principally in plants especially Legumes and also in some invertebrate which grows on the branches of decided trees, chiefly apple, poplar and plum. The present study amid to evaluate the antitumor activity of lectin against mice bearing solid tumor subcutaneously implemented with Ehrlich Ascites carcinoma (EAC) cells. The experimental mice were classified into the following groups: 1-Normal control mice group received saline solution. PDF created with pdfFactory Pro trial version www.pdffactory.com English Summary_______________________________________________________ ______________________________ _________________________________ 85 2-Mice-bearing solid tumor untreated and received saline solution (positive control mice group). 3-Mice-bearing solid tumor treated with lectin at different concentrations (650,750,850 ng/100 g body weight). The results showed that: 1- Lectin at dose of (650 ng/100 g body weight) significantly decrease tumor volume from (2.068+0.15) mm3 to (1.032+0.19) mm3, while lectin at dose of (750 ng/100 g body weight) significantly decrease the same volume to (1.624+0.94) mm3 and lectin at dose of (850 ng/100 g body weight) significantly decrease it to (1.838+0.044) mm3 respectively . This means that Lectin has antitumor activity that can regress tumor growth and at (650 ng/100 g body weight) doses is effective than other doses used . 2- Positive control animal group implemented with (EAC) exhibited a highly significant increase in IL-12 level (3.985+0.586) compared to normal control group (2.485+0.502). Lectin treated group at dose of (650ng/100 g body weight) showed a significant decrease in IL-12 level (2.545+0.565) compared to lectin treated group at dose 0f (750ng/100 g body weight) was(2.753+0.588) and lectin treated group at dose 0f (850ng/100 g body weight) was (2.655+0.573) respectively. At the mean time lectin treated group at dose 0f (850ng/100 g body weight) (2.655+0.573) exhibited a significant increase compared to lectin treated group at dose 0f (750ng/100 g body weight) (2.753+0.588). PDF created with pdfFactory Pro trial version www.pdffactory.com English Summary_______________________________________________________ ______________________________ _________________________________ 86 3- Positive control animal group implemented with (EAC) exhibited a highly significant decrease in T.N.F level (3.308+0.602) compared to normal control group (5.307+1.303).Lectin treated group at dose of (650ng/100 g body weight) showed a significant increase in TNF level (5.166+1.503) compared to lectin treated group at dose 0f (750ng/100 g body weight) (4.456+1.045) and lectin treated group at dose 0f (850ng) (4.756+0.506) respectively. At the mean time lectin treated group at dose 0f (850ng) (4.756+0.506) exhibited a significant increase compared to lectin treated group at dose 0f (750ng) (4.456+1.045) 4- Liver histopathology of mice bearing Ehrlich ascites carcinoma cells treated with Lectin (650 ng /100 g body weight) showed normal central vein, normal hepatic lobules and enlarged blood sinusoids compared to control group. 5- Kidney histopathology in mice bearing Ehrlich ascites carcinoma cells treated with lectin (650ng /100 g body weight) showed dilated blood vessels and normal glomeruli with normal subcapsular space compared to control group. PDF created with pdfFactory Pro trial version www.pdffactory.com English Summary_______________________________________________________ ______________________________ _________________________________ 87 Short Summary The present study amid to evaluate the antitumor activity of lectin against mice bearing solid tumor subcutaneously implemented with Ehrlich Ascites carcinoma (EAC) cells. The experimental mice were classified into the following groups: 1-Normal control mice group received saline solution. 2-Mice-bearing solid tumor untreated and received saline solution (positive control mice group). 3-Mice-bearing solid tumor treated with lectin at different concentrations (650,750,850 ng/100 g body weight). The results showed that: 1- Lectin at dose of (650 ng/100 g body weight) significantly decrease tumor volume from (2.068+0.15) mm3 to (1.032+0.19) mm3, while lectin at dose of (750 ng/100 g body weight) significantly decrease the same volume to (1.624+0.94) mm3 and lectin at dose of (850 ng/100 g body weight) significantly decrease it to (1.838+0.044) mm3 respectively . This means that Lectin has antitumor activity that can regress tumor growth and at (650 ng/100 g body weight) doses is effective than other doses used . PDF created with pdfFactory Pro trial version www.pdffactory.com English Summary_______________________________________________________ ______________________________ _________________________________ 88 2- Positive control animal group implemented with (EAC) exhibited a highly significant increase in IL-12 level (3.985+0.586) compared to normal control group (2.485+0.502). Lectin treated group at dose of (650ng/100 g body weight) showed a significant decrease in IL-12 level (2.545+0.565) compared to lectin treated group at dose 0f (750ng/100 g body weight) was(2.753+0.588) and lectin treated group at dose 0f (850ng/100 g body weight) was (2.655+0.573) respectively. At the mean time lectin treated group at dose 0f (850ng/100 g body weight) (2.655+0.573) exhibited a significant increase compared to lectin treated group at dose 0f (750ng/100 g body weight) (2.753+0.588). 3- Positive control animal group implemented with (EAC) exhibited a highly significant decrease in T.N.F level (3.308+0.602) compared to normal control group (5.307+1.303).Lectin treated group at dose of (650ng/100 g body weight) showed a significant increase in TNF level (5.166+1.503) compared to lectin treated group at dose 0f (750ng/100 g body weight) (4.456+1.045) and lectin treated group at dose 0f (850ng) (4.756+0.506) respectively. At the mean time lectin treated group at dose 0f (850ng) (4.756+0.506) exhibited a significant increase compared to lectin treated group at dose 0f (750ng) (4.456+1.045) 4- Liver histopathology of mice bearing Ehrlich ascites carcinoma cells treated with Lectin (650 ng /100 g body weight) showed normal central vein, normal hepatic lobules and enlarged blood sinusoids compared to control group. 5- Kidney histopathology in mice bearing Ehrlich ascites carcinoma cells treated with lectin (650ng /100 g body weight) showed dilated PDF created with pdfFactory Pro trial version www.pdffactory.com English Summary_______________________________________________________ ______________________________ _________________________________ 89 blood vessels and normal glomeruli with normal subcapsular space compared to control group. |